MEIP : oncology play with many readouts in 2020, no debt and enough cash to see through 2020 (am long). SNGX: oncology/defense/diverse play with readout pending 1Q2020 and another one 2Q2020 (am long). Like with all pre-commercial biotechs risky, but great risk/reward odds. Do your own DD. Still long on ATRS (main position, 2 bagger so far) which turned profitable last Q and has tremendous growth in front of it, closed VCEL (5 bagger) and ARRY (4 bagger, eventually got bought out for even another 2 bagger left on the table).
invite response
SNGX: oncology/defense/diverse play with readout pending 1Q2020 and another one 2Q2020 (am long).
Like with all pre-commercial biotechs risky, but great risk/reward odds. Do your own DD.
Still long on ATRS (main position, 2 bagger so far) which turned profitable last Q and has tremendous growth in front of it, closed VCEL (5 bagger) and ARRY (4 bagger, eventually got bought out for even another 2 bagger left on the table).
#TrumpEconomy
#MAGA